Ad Header



The Pulse of the Pharmaceutical Industry

Could Gilead Be Biotech’s Biggest Bargain?

Written by: | | Dated: Wednesday, August 12th, 2015

Gilead Sciences (NASDAQ:GILD) shares may have rallied 24% this year, but better-than-expected sales and profit have led to analysts ratcheting up their EPS forecasts for next year and that’s kept a lid on its valuation. Given that Gilead Sciences’ forward P/E is below 10 and its shares are 5% off their June highs, the stock could be the best bargain in biotech.

Hey, check out all the research scientist jobs. Post your resume today!


Source: BioSpace Featured Stories

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom